Praxis Precision Medicines Inc

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders driven by neuronal excitation-inhibition imbalance. The company operates two proprietary drug discovery and development platforms: Cerebrum™ for small molecules and Solidus™ for antisense oligonucleotides (ASOs). Its pipeline includes four late-stage product candidates targeting movement disorders and epilepsy. Ulixacaltamide, a T-type calcium channel inhibitor, is under NDA review for Essential Tremor with a PDUFA date of January 2027. Relutrigine, a sodium channel modulator, is under priority review for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) with a PDUFA date of December 2026 and is also being studied in broader DEE populations. Vormatrigine, a next-generation sodium channel modulator, is being developed for focal onset seizures and generalized epilepsy in adults. Elsunersen, an ASO developed in collaboration with Ionis Pharmaceuticals and RogCon, targets early-seizure-onset SCN2A DEE. The company has received three Breakthrough Therapy Designations from the FDA across its portfolio and is actively building commercial infrastructure for potential near-term product launches. The company generates no product revenue and funds operations through equity offerings and interest income on its investment portfolio. Updated Aug 6, 2026